VA-VIRTUSTREAM
9.9.2020 13:02:12 CEST | Business Wire | Press release
Virtustream , an enterprise-class cloud company and Dell Technologies business, announced the availability of new start/stop automation for SAP® software landscapes and systems to help enterprises optimize their costs and controls through new self-service tools and step-by-step status updates. The functionality is now available in the Virtustream Enterprise Cloud via the xStream portal .
“Virtustream consistently drives new innovation into its Virtustream Enterprise Cloud platform to meet our demanding requirements and evolving mission-critical needs in the cloud,” says Ettore Tenaglia, Head of Service Operations, Almaviva. “The new automated features and tools help to improve our oversight, management and controls of our SAP environments, allowing us to optimize our processes to save valuable time and costs which can go back into our business.”
Address Compute Costs with Workload Automation
Virtustream’s new automated services reduce the amount of time and manual effort required from an organization’s internal IT team to perform start/stop commands on SAP landscapes and systems. The new tools and features include:
- Strategic Scheduling: Start/stop operations can be scheduled through the Virtustream xStream portal in 30-minute windows on a one-time, on-demand, or recurring basis (daily, weekly or free-form). Additionally, users can set an expiration date for the agentless operation. Creating customized schedules to power virtual machines on or off helps to reduce compute costs. Additionally, automatically shutting down applications when they aren’t being used, such as during weekends and maintenance periods, can further optimize costs.
- Defined Prioritization: Customers can assign each SAP system a set priority, allowing them to stagger the start/stop of their system so they proceed in a defined order, helping to ensure applications run efficiently and correctly.
- Improved Access Control: Only approved administrators or users can access and use the start/stop automation, as dictated by the enterprise’s permission controls within their xStream tenant.
- New Status Updates, Customized Notifications and Action Logs: A new status bar indicates the step-by-step process of each action as it progresses through the SAP system or landscape. Additionally, customized email notifications can be sent to each administrator based on actions (all actions or only scheduled) or by result (all results or failed only). An action log is generated for each system that shows all actions run on a specific SAP system or landscape including who initiated the action, when it was completed, and what actions were taken.
“Automation is key to streamlining IT operations and increasing cloud agility while freeing internal resources to focus on higher-priority projects or initiatives,” says Mike Zolla, Vice President of Cloud Platform Engineering and Delivery, Virtustream. “By extending automation deeper into our mission-critical Virtustream Enterprise Cloud platform, we are helping our enterprise customers increase the economic and business benefits of their SAP applications.”
Backed by Virtustream’s extensive experience migrating, optimizing and managing SAP workloads in the cloud, Virtustream’s new start/stop automation capability is available across all xStream-supported databases. Virtustream’s xStream Management Platform provides a powerful cloud management platform with a single interface across complex, distributed IT environments. xStream delivers economic and business benefits for a broad range of mission-critical enterprise applications in the cloud.
About Virtustream
Virtustream LLC, a Dell Technologies business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies, Virtustream’s xStreamCare professional and managed services, and the xStream® Management Platform and Infrastructure-as-a-Service (IaaS) meet the security, compliance, performance, efficiency, and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom